The Future of Patentable DNA: A Myriad of Possibilities

Summary

On Thursday, June 13, 2013, the Supreme Court held that a patent claim directed to “an isolated DNA molecule” was not patent eligible under 35 U.S.C. §101 solely because the DNA molecule had been “isolated” from the rest of the genome. The Court found, however, that a cDNA (complementary DNA) molecule may be patent eligible, because a cDNA molecule is “not found in nature.” This conclusion assumes that a cDNA molecule is different from the genomic sequence because it lacks intron sequences.1

This holding potentially impacts claims directed to prokaryotic nucleic acid sequences, short segments of eukaryotic nucleic acid, regulatory regions and/or promoters, isolated proteins, antibodies, naturally occurring mutations such as SNPs, regulatory RNA sequences, such as siRNA, RNAi, shRNA, etc., and arrays.

1 Genomic DNA comprises both introns (non-coding regions of DNA) and exons (coding regions). In vivo, genomic DNA is transcribed to RNA and processed to remove the introns. The complementary DNA to the processed RNA molecule is referred to as cDNA, and due to the lack of introns, the cDNA molecule is not the same as the genomic sequence.
As a result, we strongly recommend reviewing your patent estate to determine the potential impact of the Myriad decision and, if necessary, to devise new claim strategies. If a claim in your estate is directed to a sequence that may be found in a cell or organism, the claim may be invalid as directed to an unpatentable product of nature.

For issued patents, we recommend analyzing the benefit of a reissue application to potentially redraft any claims that may be held invalid. For new or presently pending claims, we recommend redrafting the claims to encompass a sequence element that is not found in a cell or organism.

In addition to evaluating your own estate, it may be beneficial to use the Myriad decision offensively against competitors. Please contact a member of the Science and Technology practice for more details.

Case Analysis

The present case (Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al.) stems from Myriad’s research and patents surrounding the BRCA1 and BRCA2 sequences. Specific variants, or mutations, of these sequences are associated with a significantly increased risk of breast and ovarian cancer in afflicted women. Myriad built a patent estate around this discovery, including claims to the isolated BRCA1 and BRCA2 sequences. These patents² were challenged under §101 of the Patent Act, with the challengers alleging that “isolated” sequences are not patent eligible because despite the fact that the sequences are no longer within the human body, they are still products of nature.

The Supreme Court has “long held that [Section 101 of the Patent Act] contains an important implicit exception

² The patents at issue include claims 1, 2, 5, 6, and 7 of US Patent 5,747,282, claim 1 of US Patent 5,693,473, and claims 1, 6, and 7 of US Patent 5,837,492.
DNA, is a nucleic acid sequence that is complementary to the mRNA for a particular gene. Eukaryotic cDNA sequence lacks introns derived from the genomic sequence, and therefore, is not a sequence that would be “found in nature,” but rather, is lab created. Hence, the Court found that cDNA was patent eligible under §101 because it is not a “product of nature.”

The Supreme Court addressed arguments that the Court should find “isolated” sequences patent eligible due to reliance on the Patent Office’s history of allowing such claims by indicating that such reliance concerns “are better directed to Congress.”

Implications

- Prokaryotic Nucleic Acid Sequences

  Prokaryotic chromosomes do not comprise introns. Therefore, it would appear that bacterial nucleic acid sequences, by themselves, are no longer patent eligible, as there is not a way to produce a cDNA molecule that is “not found in nature.” Even if a court found that a cDNA molecule derived from a prokaryotic organism was eligible under §101 by virtue of being lab manipulated, it would seem that such a sequence would minimally be subject to challenge under §103 for obviousness in light of the genomic sequence.

  It may, however, be possible to claim a prokaryotic sequence that is operably linked to a different promoter, or that is fused with a different genetic segment, so as to create a sequence “not found in nature.” In this manner, vectors may be patent eligible.

- Short Segments of Eukaryotic DNA

  As short segments of eukaryotic DNA may not cross an intron/exon boundary, it appears that they would also no longer be patent eligible, because similar to prokaryotic sequences, there is not a way to produce a cDNA molecule that is “not found in nature.” This would impact claims directed to, for example, 15 contiguous nucleotides of a particular genetic sequence. It may also impact claims to probes, and claims to single nucleotide polymorphisms (SNPs).

- Promoters/Regulatory regions

  The Court’s decision only seemed to address coding regions of the genome. Non-coding regions, such as promoters, enhancers, repressors, etc. were not mentioned. However, as none of these sequences, on their own, can be manipulated in a manner analogous to the creation of cDNA it would appear that these sequences are no longer patent eligible either.

  It may, however, be possible to create “new” regulatory “regions” that combine a promoter and regulatory sequences in an order or manner not found in nature.

- Isolated Proteins

  The Court’s decision did not directly address the patent eligibility of isolated protein sequences. Following the Court’s logic, however, it would appear that a claim directed to an “isolated” protein, and nothing more, may no longer be patent eligible as such a protein may “be found in nature.”

  It would appear that fusion proteins, or other manipulated proteins may still be patent eligible by virtue of the fact that they are “not found in nature.”
• Antibodies

An antibody is a specific type of protein. Generically speaking, researchers will use the innate ability of an organism to develop antibodies against a particular target antigen, and then isolate the antibody or antibody-producing cell from the organism. It is not clear how such isolation techniques will be addressed under the Myriad decision.

It may, however, be possible to claim a hybridoma, as the hybridoma is a cell fusion that is not found in nature. It may also be possible to claim chimeric antibodies, humanized antibodies, or single chain antibodies, for instance, as those antibodies are not sequences typically “found in nature.”

• Mutations

The Court specifically mentions that it is not making a decision on the application of §101 to genetic sequences that have been altered. It would appear, though, that claims to mutations that are found in nature, even if not “wild-type” would be patent ineligible.

Mutations that fuse two heterologous sequences, or that mutate a sequence to something that has not yet been seen in nature, however, would still seem to be patent eligible.

• Regulatory RNA sequences

A great deal of research has focused on small RNA molecules that regulate transcription in a cell – these include RNAi, siRNA, and shRNA. The status of claims to these sequences is not immediately clear, and will most likely have to be determined on a case by case basis with the test being whether the sequences would be “found in nature” or whether they are artificial lab constructs.

• Genetically modified organisms

Genetically modified organisms still appear to be patent eligible. These organisms, as explained by the Court, do not appear in nature. And the Court seemed to endorse the Chakrabarty decision as still being good law.

Suggestions

In light of the June 13th decision, we strongly recommend reviewing your patent estate to determine which claims may be impacted by this decision.

Issued Patents:

If claims in an issued patent are directed to unpatentable sequences, we recommend analyzing the patent to determine if a reissue application will be helpful. If the application is within two years of issuance, this procedure may be of great significance in maintaining patent validity. If the patent has been issued for more than two years, a reissue may still offer a solution if the claim is narrowed. This may, for instance, be possible by adding a limitation to the claim that is not found in nature.

New or Presently Pending Applications:

For presently pending applications, we recommend analyzing the specification for potential claim elements that are not found in nature, but that are not
unnecessarily restricting. For instance, it may be possible to claim a vector comprising the nucleic acid sequence, without specifically indicating any other components of the vector.³

For new applications, we recommend defining terms in the specification to exclude sequences found in nature. For instance, in reference to antibodies, the term “chimeric” may be defined as “at least one amino acid change from the wild-type sequence.” This definition indicates the claimed sequence is not found in nature, while not being excessively restricting. All such amendments, however, should also be viewed in light of potential written description-enablement, novelty, and obviousness issues.

For More Information

If you would like a more detailed analysis of your specific claims, please contact us. In addition, we expect that the US Patent and Trademark Office will soon issue Examiner guidelines that reflect the changes brought by the Myriad decision. Similarly, lower court decisions in the coming months will also elucidate the scope of the Myriad decision. We are monitoring such cases and will keep you informed of new developments.

For more information, please contact:

- **Patrick C. Woolley** | 816.360.4280 | pwoolley@polsinelli.com *(Kansas City)*
- **Kathryn J. Doty** | 314.552.6850 | kdoty@polsinelli.com *(Edwardsville, St. Louis)*
- **Teddy C. Scott, Ph.D** | 312.873.3613 | tscott@polsinelli.com *(Chicago)*
- **Rebecca Riley-Vargas, Ph.D.** | 312.463.6312 | rriley-vargas@polsinelli.com *(Chicago)*
- **Tracey S. Truitt** | 816.572.4604 | ttruitt@polsinelli.com *(Kansas City)*
- **Tara A. Nealey, Ph.D.** | 314.622.6630 | tnealey@polsinelli.com *(St. Louis)*

³ It is not clear, however, how the courts or the Patent Office will view the obviousness of such claims.
About Our Science & Technology Practice

Polsinelli protects creativity and encourages the growth of knowledge in the science and technology industries. The Science and Technology Law group brings considerable resources and experience to entrepreneurial work by focusing on the special needs of clean technology, biotechnology, chemical, food science, pharmaceutical, bioinformatic, medical device, computer hardware, software, electronic commerce and new media companies, as well as universities and government laboratories. Staffed with experienced lawyers and scientists with advanced degrees in engineering, biology, microbiology, and chemistry, to name a few, our attorneys handle the most complex and cutting edge issues facing technology, high-tech, bioscience, consumer food products, animal science, medical device, agriculture and clean technology industries.

The science and technology law group provides legal counsel on issues that today’s science and technology companies encounter, from the obvious to the oblique. Our attorneys have partnered with many of our clients from their first day of business and helped them grow and prosper into successful and innovative enterprises.

To learn more about our services, visit us online at www.polsinelli.com.

Patrick C. Woolley  
Practice Area Chair  
Kansas City  
816.360.4280  
pwoolley@polsinelli.com

Gregory P. Durbin  
Practice Area Vice Chair  
Denver  
720.931.8133  
gdurbin@polsinelli.com

Ari M. Bai  
Phoenix  
314.552.6855  
abai@polsinelli.com

Briana R. Barron  
Kansas City  
816.360.4304  
b barric@polsinelli.com

John R. Bednarz  
Washington, D.C.  
202.626.8307  
jbednarz@polsinelli.com

Yu Cai, Ph.D.  
Phoenix  
602.650.2044  
ycai@polsinelli.com

Corey Casey  
Kansas City  
816.572.4439  
c casey@polsinelli.com

Christine M. Cochran  
Chicago  
312.463.6316  
ccochran@polsinelli.com

Bradley W. Crawford  
Chicago  
312.873.2992  
bcrawford@polsinelli.com

Elton F. Dean III  
St. Louis  
314.622.6632  
edean@polsinelli.com

Karen R. Dickinson  
Phoenix  
602.650.2328  
kdickinson@polsinelli.com

Brian B. Diekhoff  
St. Louis  
314.552.6837  
b diekhoff@polsinelli.com

Derek D. Donahoe  
Denver  
720.931.8160  
ddonahoe@polsinelli.com

Michael J. Donovan, Ph.D.  
Phoenix  
602.650.2347  
mdonovan@polsinelli.com

Kathryn J. Doty  
Edwardsville, St. Louis  
314.552.6850  
kdoty@polsinelli.com

Taryn A. Elliot  
Denver  
303.583.8243  
telliott@polsinelli.com

Robert O. Enyard Jr.  
St. Louis  
314.552.6862  
renyard@polsinelli.com

Daniel L. Farris  
Chicago  
312.463.6323  
dfarris@polsinelli.com

Jeffrey E. Fine  
St. Louis  
314.552.6824  
jfine@polsinelli.com

Ron Galant, Ph.D.  
Chicago  
312.873.3633  
gr galant@polsinelli.com

Eric R. Gray  
Kansas City  
816.572.4549  
egray@polsinelli.com

Christopher L.E. Hines  
St. Louis  
314.622.6636  
c hines@polsinelli.com

Kimberly A. Honeycutt, Ph.D.  
Kansas City  
816.572.4884  
k honeycutt@polsinelli.com

S. Wade Johnson  
Denver  
720.931.8134  
wadejohnson@polsinelli.com

© 2013 Polsinelli
<table>
<thead>
<tr>
<th>Name</th>
<th>City</th>
<th>Phone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristin A. Kenney</td>
<td>Kansas City</td>
<td>816.572.4526</td>
<td><a href="mailto:kkenney@polsinelli.com">kkenney@polsinelli.com</a></td>
</tr>
<tr>
<td>J. Morgan Kirley</td>
<td>Chicago</td>
<td>312.873.3624</td>
<td><a href="mailto:mkirley@polsinelli.com">mkirley@polsinelli.com</a></td>
</tr>
<tr>
<td>Gregory M. Kratofil Jr.</td>
<td>Kansas City</td>
<td>816.360.4363</td>
<td><a href="mailto:gkratofil@polsinelli.com">gkratofil@polsinelli.com</a></td>
</tr>
<tr>
<td>Carla M. Lee</td>
<td>Kansas City</td>
<td>816.572.4882</td>
<td><a href="mailto:clee@polsinelli.com">clee@polsinelli.com</a></td>
</tr>
<tr>
<td>Michael P. Narducci</td>
<td>Phoenix</td>
<td>602.650.2099</td>
<td><a href="mailto:mnarducci@polsinelli.com">mnarducci@polsinelli.com</a></td>
</tr>
<tr>
<td>Tara A. Nealey</td>
<td>St. Louis</td>
<td>314.622.6630</td>
<td><a href="mailto:tnealey@polsinelli.com">tnealey@polsinelli.com</a></td>
</tr>
<tr>
<td>Gregory W. O’Connor</td>
<td>Denver</td>
<td>303.583.8248</td>
<td><a href="mailto:goconnor@polsinelli.com">goconnor@polsinelli.com</a></td>
</tr>
<tr>
<td>Jay E. Pietig</td>
<td>Kansas City</td>
<td>816.360.4183</td>
<td><a href="mailto:jpietig@polsinelli.com">jpietig@polsinelli.com</a></td>
</tr>
<tr>
<td>Andrea M. Porterfield</td>
<td>Kansas City</td>
<td>816.360.4119</td>
<td><a href="mailto:aporterfield@polsinelli.com">aporterfield@polsinelli.com</a></td>
</tr>
<tr>
<td>Joshua J. Pranckun</td>
<td>Denver</td>
<td>303.583.8269</td>
<td><a href="mailto:jpranckun@polsinelli.com">jpranckun@polsinelli.com</a></td>
</tr>
<tr>
<td>Rebecca C. Riley-Vargas, Ph.D.</td>
<td>Chicago</td>
<td>312.463.6312</td>
<td><a href="mailto:rriley-vargas@polsinelli.com">rriley-vargas@polsinelli.com</a></td>
</tr>
<tr>
<td>Marcia J. Rodgers</td>
<td>Kansas City</td>
<td>816.374.0523</td>
<td><a href="mailto:mrogers@polsinelli.com">mrogers@polsinelli.com</a></td>
</tr>
<tr>
<td>Brian R. Salmo</td>
<td>St. Louis</td>
<td>314.622.6637</td>
<td><a href="mailto:bsalmo@polsinelli.com">bsalmo@polsinelli.com</a></td>
</tr>
<tr>
<td>Kelley A. Schnieders</td>
<td>Kansas City</td>
<td>816.572.4605</td>
<td><a href="mailto:kschnieders@polsinelli.com">kschnieders@polsinelli.com</a></td>
</tr>
<tr>
<td>Teddy C. Scott, Ph.D.</td>
<td>Chicago</td>
<td>312.873.3613</td>
<td><a href="mailto:tsctt@polsinelli.com">tsctt@polsinelli.com</a></td>
</tr>
<tr>
<td>Matthew J. Smith</td>
<td>St. Louis, Edwardsville</td>
<td>314.552.6879</td>
<td><a href="mailto:msmith@polsinelli.com">msmith@polsinelli.com</a></td>
</tr>
<tr>
<td>Timothy D. Steffens</td>
<td>Kansas City</td>
<td>816.572.4595</td>
<td><a href="mailto:tsteffens@polsinelli.com">tsteffens@polsinelli.com</a></td>
</tr>
<tr>
<td>James M. Stipek</td>
<td>Kansas City</td>
<td>816.360.4191</td>
<td><a href="mailto:jstipek@polsinelli.com">jstipek@polsinelli.com</a></td>
</tr>
<tr>
<td>Richard P. Stitt</td>
<td>Overland Park</td>
<td>913.234.7524</td>
<td><a href="mailto:rstitt@polsinelli.com">rstitt@polsinelli.com</a></td>
</tr>
<tr>
<td>Karin E. Sullivan</td>
<td>Denver</td>
<td>303.583.8244</td>
<td><a href="mailto:ksullivan@polsinelli.com">ksullivan@polsinelli.com</a></td>
</tr>
<tr>
<td>Lawrence A. Swain</td>
<td>Overland Park</td>
<td>913.234.7526</td>
<td><a href="mailto:lswain@polsinelli.com">lswain@polsinelli.com</a></td>
</tr>
<tr>
<td>Tracey S. Truitt</td>
<td>Kansas City</td>
<td>816.572.4604</td>
<td><a href="mailto:ttruitt@polsinelli.com">ttruitt@polsinelli.com</a></td>
</tr>
<tr>
<td>Michael A. Williamson</td>
<td>Kansas City</td>
<td>816.360.4168</td>
<td><a href="mailto:mwilliamson@polsinelli.com">mwilliamson@polsinelli.com</a></td>
</tr>
<tr>
<td>Spencer R. Wood</td>
<td>Chicago</td>
<td>312.873.3677</td>
<td><a href="mailto:swood@polsinelli.com">swood@polsinelli.com</a></td>
</tr>
<tr>
<td>David M. Zamora</td>
<td>Denver</td>
<td>303.583.8274</td>
<td><a href="mailto:dzamora@polsinelli.com">dzamora@polsinelli.com</a></td>
</tr>
</tbody>
</table>
About Polsinelli

Real Challenges. Real Answers.SM Serving corporations, institutions, entrepreneurs, and individuals, our attorneys build enduring relationships by providing legal counsel informed by business insight to help clients achieve their objectives. This commitment to understanding our clients' businesses has helped us become the fastest growing law firm in the U.S. for the past five years, according to the leading legal business and law firm publication, The American Lawyer. With more than 660 attorneys in 17 cities, our national law firm is a recognized leader in the industries driving our growth, including health care, financial services, real estate, life sciences and technology, energy and business litigation. The firm can be found online at www.polsinelli.com.

Polsinelli PC. In California, Polsinelli LLP.

About this Publication

If you know of anyone who you believe would like to receive our e-mail updates, or if you would like to be removed from our e-distribution list, please contact Kim Auther via e-mail at KAuthor@polsinelli.com.

Polsinelli provides this material for informational purposes only. The material provided herein is general and is not intended to be legal advice. Nothing herein should be relied upon or used without consulting a lawyer to consider your specific circumstances, possible changes to applicable laws, rules and regulations and other legal issues. Receipt of this material does not establish an attorney-client relationship.

Polsinelli is very proud of the results we obtain for our clients, but you should know that past results do not guarantee future results; that every case is different and must be judged on its own merits; and that the choice of a lawyer is an important decision and should not be based solely upon advertisements.

Polsinelli PC. In California, Polsinelli LLP.